Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

NCT00035282

Major Depressive Disorder

COMPLETED PHASE3

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555

Depression

TERMINATED PHASE2

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295

Major Depressive Disorder

COMPLETED PHASE3

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552

Major Depressive Disorder (MDD)

TERMINATED PHASE3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401

Major Depressive Disorder

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As the understanding of the complex relationship between pro-inflammatory cytokines (specifically interleukin-6 \[IL-6\]) and depression symptoms becomes clearer, clinical trials to evaluate effective and novel treatments are needed. As there have been no published tocilizumab trials among patients with major depression, this pilot study will adopt a single-arm, open-label design. Due to the notion that inflammatory cytokines may play a role in a sub-type of depression, this study will recruit patients with treatment refractory major depressive disorder, for whom established depression treatments have not been effective. In conducting this trial, the investigators seek to examine the potential role of tocilizumab as an augmentation agent, with the hypothesis that it could reduce depression symptomatology in patients with major depression who have not experienced symptom reduction through more traditional antidepressant therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tocilizumab

Tocilizumab 162 mg sc q2weeks x 4 doses

Group Type EXPERIMENTAL

Tocilizumab

Intervention Type DRUG

Subcutaneous tocilizumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocilizumab

Subcutaneous tocilizumab

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Actemra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current diagnosis of major depressive episode
* Hamilton Depression Rating Scale (HDRS) score of \>20
* In treatment for depression for a minimum of 8 weeks

Exclusion Criteria

* Active drug or alcohol disorder in the last three months
* History of psychosis, mania or hypomania
* Acute suicide or homicide risk
* History of liver disease including HCV and HBV
* HIV
* History of heart disease or a heart attack
* Active or latent tuberculosis, a history of a positive tuberculosis test, or having received the Bacillus Calmette-Guérin (BCG) vaccine
* Epilepsy or a history of seizures
* Abnormal thyroid-stimulating hormone (TSH \<0.4 or \>5.0mlU/L)
* Abnormal liver function tests on screening (ALT\>50 U/L or AST\>50 U/L)
* Low absolute neutrophil count (ANC) on screening (\<4000/mm3
* Abnormal white blood cell count (\<4,500 or \> 10,000mcL)
* Low platelet count on screening (\<150,000/mm3
* Patients with an active or recent infection, for example cellulitis, bacteremia, pneumonia, and pyelonephritis.
* Recent exposure to uncommon infections (e.g. histoplasmosis, blastomycosis, coccidiomycosis) through recent travel to the Ohio and Mississippi River Valleys and the Southwest
* Pregnant women, breastfeeding women or women of child-bearing age not using contraception
* History of or current autoimmune disease, including multiple sclerosis and inflammatory bowel disease
* Diagnosis of chronic fatigue syndrome
* Temperature greater than 100.3F at the screening visit or any subsequent visits
* Dyslipidemia
* Currently taking oral steroids
* Currently taking statins
* Chronic aspirin or NSAID takers
* Currently taking any immunomodulating medications
* Inability to consent due to cognitive impairment

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No